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There are no published data on the number of invasive procedures 
done in South Africa, but unpublished data from national laboratories 
suggest that the services are under-utilised.1   In 2008, 6 out of 7 national 
laboratories received 529 amniocentesis specimens done for advanced 
maternal age – this in a background of 1 049 300 live births.1,2
In a high HIV prevalence setting like South Africa, where the estimated 
prevalence in antenatal clinic attendees was 29.4% in 2009, a significant 
proportion of pregnant women in need of invasive procedures will be 
HIV-infected.3 HIV clinicians need to be aware of the risk of mother-to-
child transmission of HIV (MTCT) associated with invasive procedures, 
and should also be aware of strategies available to minimise the risk. 
This information needs to be given to clients during the counselling 
session before the procedure, and HIV clinicians may also be asked to 
advise obstetric colleagues on optimal management in cases where a 
HIV-infected woman requires a prenatal invasive procedure.
TIMING OF INVASIVE PROCEDURES IN PREGNANC Y
Below is a list of commonly performed antenatal invasive obstetric 
procedures and the gestational age at which each procedure can, or 
should, be performed.
n Amniocentesis: from 16 weeks
n Chorionic villus sampling: from 11 to 14 weeks
n Cordocentesis: from 20 weeks
n Fetoscopy: usually in the 2nd and 3rd trimesters
n  Fetal tissue sampling (biopsies of organs, muscle, etc.): usually in 
the 2nd and 3rd trimesters
n  Aspiration of various fetal cavities, shunt insertion: any gestational 
age – usually from 16 weeks
n Embryo reductions: from 11 weeks.
Several complications may occur with invasive procedures, and as 
part of pre-procedure counselling the woman/couple should be made 
aware of the risk of procedure-related complications. These include 
injury to maternal bowel, fetal injury, failure to obtain a sample, 
chorio-amnionitis, and most significantly fetal loss.4 The Royal College 
of Obstetricians and Gynaecologists guideline on amniocentesis and 
chorionic villus sampling advises that patients should be informed 
of an additional 1% risk of fetal loss following an amniocentesis, 
and a slightly higher risk following chorionic villus sampling.5 A 
2003 Cochrane Review advises that, for second-trimester testing, 
amniocentesis is the safer procedure – safer than early amniocentesis 
or transcervical chorionic villus sampling.6 For testing before 15 weeks 
of pregnancy, transabdominal chorionic villus sampling is the safer 
procedure.6 There is no literature to suggest that the risk of procedure-
related complications is higher in HIV-infected women.
RISK OF MTCT WITH ANTENATAL INVASIVE PROCEDURES
There is limited literature on invasive obstetric procedures in the 
context of maternal HIV infection. Few studies have been published on 
the topic, most with a small number of patients. Important risk factors 
for MTCT such as maternal HIV viral load and CD4+ cell count are not 
always controlled for, and it may be difficult to infer causality in the 
reported cases of transmission after an invasive procedure. Without any 
maternal antiretroviral therapy initiated before an invasive procedure 
the risk of MTCT with invasive obstetric procedures is high, with rates of 
over 30% reported in some studies.7 In one study evaluating the effect 
of various factors on the risk on MTCT, third-trimester amniocentesis 
without any antiretroviral cover was associated with a fourfold increase 
in the risk of MTCT.8 
Antenatal invasive obstetric procedures may be diagnostic or therapeutic, and are performed at different stages of pregnancy for various indications. The most 
common indication for an invasive procedure during pregnancy is for fetal karyotyping when a chromosomal abnormality or a genetic defect is suspected, either 
from the couple’s history or from ultrasound assessment of the fetus. Other less common but equally important indications may be diagnostic (fetoscopy, fetal 
tissue sampling, estimation of fetal haemoglobin) or therapeutic (aspiration of various fetal cavities, fetal blood transfusion and embryo reductions). In a high 
HIV prevalence setting like South Africa, a significant proportion of pregnant women in need of invasive procedures will be HIV-infected.
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With the use of combination antiretroviral therapy before antenatal 
invasive procedures, the risk of MTCT is reported to be similar to 
that of a HIV-infected pregnant woman who has not had an invasive 
procedure.9-11 In studies reporting no MTCT with combination 
antiretroviral therapy, a significant number of women were initiated 
on therapy before conception, and the majority were virally suppressed 
at the time of the procedure.9 Despite the decrease in HIV transmission 
with antiretroviral cover, procedures that require more technical skills 
– such as chorionic villus sampling and cordocentesis – should still be 
avoided in the HIV-infected woman, as the risk of transmission to the 
fetus may be considerably increased. 
Guidelines on the techniques of performing invasive procedures should 
be adhered to, and where possible the transplacental route should be 
avoided owing to the higher risk of transmission.12
RECOMMENDATIONS ON ANTIRETROVIRAL 
PROPHYLAXIS PRIOR TO INVASIVE PROCEDURES
There is now general consensus that any HIV-infected pregnant woman 
who needs to undergo an invasive obstetric procedure should have 
combination antiretroviral therapy initiated before the procedure, 
regardless of maternal CD4+ cell count.12,13 Ideally, antiretroviral 
therapy should be initiated at least 4 - 6 weeks prior to the procedure 
to achieve a significant level of maternal HIV viral suppression.14 If 
the gestational age precludes waiting for the period of 4 - 6 weeks, 
the clinician can still go ahead with the procedure as continuation of 
combination antiretroviral therapy after the procedure should provide 
post-exposure prophylaxis. There is, however, no evidence on the role 
of post-procedure combination antiretroviral therapy as post-exposure 
prophylaxis, but an analogy between needling procedures and needle-
stick injuries has been made. 
There are no data available to suggest a viral load at which HIV 
transmission is unlikely to occur with an antenatal invasive procedure, 
and data from general MTCT studies cannot be extrapolated to 
cases with invasive procedures. However, both the Royal College of 
Obstetricians and Gynaecologists and the British HIV Association 
recommend an undetectable maternal viral load at the time of the 
invasive procedure.12,13 If resources allow and there is sufficient time to 
wait before the invasive procedure, the maternal viral load should be 
determined as part of pre-procedure counselling.
In a high HIV prevalence setting like South Africa, it is advisable that a 
repeat HIV test be offered immediately before the invasive procedure if 
a woman has initially tested HIV-negative early in pregnancy.
Although there are no well-established approaches for managing 
HIV-infected women undergoing invasive procedures, international 
guidelines and literature published on the topic do offer guidance for 
the clinician. Local guidelines that are in line with international best 
practices, but also account for the nature of HIV/AIDS and obstetric 
practice in South Africa, are required to guide local clinicians.   
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